Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 3/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 5/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15750383 | 0.82 | CTSD (0.51) | CTSDRENBACE1ADAM17 | |
| SCHEMBL15727261 | 0.82 | CTSD (0.51) | CTSDRENBACE1ADAM17 | |
| SCHEMBL15750326 | 0.81 | CTSD (0.46) | CTSDRENBACE1ADAM17 | |
| SCHEMBL15727173 | 0.81 | CTSD (0.46) | CTSDRENBACE1ADAM17 | |
| SCHEMBL15727227 | 0.78 | CTSD (0.51) | CTSDBACE1ADAM17 | |
| SCHEMBL15727185 | 0.77 | CTSD (0.46) | CTSDBACE1KLK7KLK5ADAM17 | |
| SCHEMBL3588065 | 0.77 | HDAC1 (0.52) | TLR2TLR1KLK7KLK5MDM2 | |
| SCHEMBL15727299 | 0.75 | CTSD (0.53) | CTSDRENBACE1 | |
| SCHEMBL19542142 | 0.74 | TLR2 (0.51) | TLR2TLR1KLK7KLK5MDM2 | |
| SCHEMBL3579032 | 0.74 | HDAC4 (0.49) | TLR2TLR1MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CTSD 271/4885TLR2 774/4885TLR1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.